Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
César SerranoAlessandro LealYanan KuangJeffrey A MorganConstance M BarysauskasJillian A PhallenOlivia TriplettAdrián Mariño-EnríquezAndrew J WagnerGeorge D DemetriVictor E VelculescuCloud P PaweletzJonathan A FletcherSuzanne GeorgePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Sunitinib and regorafenib combination is feasible and tolerable. Rapid alternation of TKIs with complementary activity might be effective when combining drugs with favorable pharmacokinetics, potentially allowing active doses while minimizing adverse events. Serial monitoring with ctDNA may guide treatment in patients with GIST.